Combination Therapy with Tesetaxel and Capecitabine Improves PFS in HER2-, HR+ Metastatic Breast Cancer
December 11th 2020
December 11, 2020 - Patients with human epidermal growth factor receptor 2-negative, hormone receptor-positive metastatic breast cancer who were treated with tesetaxel and a reduced dose of capecitabine experienced improvements in progression-free survival compared with those treated with the FDA-approved dose of capecitabine alone.